← Stock Trading Canary · All insider profiles
INSIDER PROFILE · SE
Christine Lind
Styrelseledamot | Verkställande direktör (VD)
Profile key: se|christine lind
Purchase history
- Companies traded
- 2
- Purchases · 12M
- 9
- Purchases · 24M
- 29
- Average purchase
- SEK 285,820
- Gross purchase value
- SEK 8,288,768
- Last purchase
- 2026-04-21
- Completed 20D events
- 10.0
- Outcome status
- PASS
Latest company: XSpray Pharma AB (publ)
Companies: Bactiguard Holding AB | XSpray Pharma AB (publ)
Post-purchase outcomes
Benchmark-relative outcomes are available against OMX Stockholm 30.
- Excess return = stock return − OMX Stockholm 30 return over the same period.
- Hit rate = positive excess-return events ÷ completed events.
- Price coverage = valid point-in-time prices ÷ events mature enough for that period.
- Returns start on the first shared trading session on or after publication.
| Period | Completed events | Price coverage | Hit rate | Median excess return | Average excess return | Worst excess return |
|---|---|---|---|---|---|---|
| 5D | 10Developing | 100.0% (10/10) | 30.0% (3/10) | -2.7% | -2.0% | -9.2% |
| 20D | 10Developing | 100.0% (10/10) | 10.0% (1/10) | -10.0% | -13.1% | -48.9% |
| 60D | 10Developing | 100.0% (10/10) | 0.0% (0/10) | -38.7% | -32.3% | -56.7% |
| 120D | 10Developing | 100.0% (10/10) | 0.0% (0/10) | -57.9% | -46.1% | -65.9% |
Research patterns
- First purchase in 12M
- 2/7
- Large purchase ≥ €100k
- 2/10
- Cluster buying · 15D
- 3/10
- Buying the dip · ≥20% below prior 52W high
- 10/10
- Routine / opportunistic
- Not classifiable
Counts are profile-wide, point-in-time research labels. They never affect the insider score or ranking.
Every completed outcome is shown; n<5 is descriptive small-sample evidence and is not scored. Disclosure-level observations published on the same date may share a return path and may not be statistically independent. These results never affect the insider score or ranking.